tldrdailynews.com logo

Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials

1 min read
Source: STAT
Amgen's Weight-Loss Drug Faces Challenges and Adjustments in Trials
Photo: STAT
TL;DR

Amgen's obesity drug MariTide showed significant weight loss in a Phase 2 trial but had high side effects and discontinuation rates, prompting the company to plan a slower dosing schedule for future testing.

Topics:businesshealth#amgen#clinical-trial#health#maritide#obesity-drug#weight-loss
Share this article
  1. Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing  STAT
  2. Monthly weight loss drug helps people lose 20% of body weight, trial finds  NBC News
  3. Amgen gears up for phase 3 trial of monthly weight-loss drug MariTide amid mixed investor sentiment  Yahoo Finance
  4. Amgen Shares Fall on Weight-Loss Drug Tummy Troubles  Barron's
  5. ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half  FirstWord Pharma

Want the full story? Read the original reporting

Read on STAT